BrainSight AI, a deep-tech neuroscience startup, has raised $5 million in a pre-Series A funding round led by IAN Alpha Fund. IvyCap Ventures, Silver Needle, and its current investors also participated.
Pfizer and other investors had previously contributed $925K to the Bengaluru-based company.
According to a press release from BrainSight, the new funding will be used to improve R&D capabilities, increase reach in Tier I and Tier II cities, expand into Africa, Southeast Asia, the US, and allied markets, and increase the company’s presence in India.
BrainSight AI was co-founded in 2019 by Laina Emmanuel and Rimjhim Agrawal with the goal of facilitating more accurate diagnosis and treatment planning for neuropsychiatric and neuro-oncological conditions. To enable accuracy in neurological and psychiatric investigations for quicker patient outcomes, the platform integrates artificial intelligence and neuroscience.
BrainSight claims that its platform products include Snowdrop, a patient care app that facilitates adherence to treatment plans and creates patient profiles, and Voxelbox, which gives clinicians access to an fMRI processing engine and machine-learning models.
As of right now, BrainSight AI claims to work with more than 40 top hospitals in India, specializing in radiology and neurosurgery departments that handle brain tumor cases.
The business is now offering more comprehensive treatments for mental and neurological conditions, opening the door for a more all-encompassing method of brain care.
By mapping the brain’s macro-scale neural connections, BrainSight AI facilitates accurate diagnosis and prognosis of neuro-psychiatric and neuro-oncological conditions, thereby shedding light on the relationship between the physiology and functions of the brain.
